Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-A and pigment epithelium-derived factor in neovascular glaucoma.
Jia Wei Wang, Min Wen Zhou, Xiulan Zhang, Wen Bin Huang, Xin Bo Gao, Wei Wang, Shida Chen, Xin Yu Zhang, Xiao Yan Ding, Jost B Jonas
Summary
Aqueous concentrations of VEGF-A and PEDF were significantly elevated in eyes with neovascular glaucoma.
Abstract
BACKGROUND
This study aims to evaluate concentrations of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF)-A in aqueous of patients with neovascular glaucoma prior to, and shortly after, an intravitreal ranibizumab injection.
DESIGN
Interventional comparative study.
PARTICIPANTS
The study included patients undergoing an intravitreal ranibizumab injection about one week before anti-glaucomatous surgery (study group) or who underwent routine cataract surgery (control group).
METHODS
Aqueous and blood samples were collected at the occasions of intravitreal injections, anti-glaucomatous surgery or cataract surgery. They were analysed by enzyme-linked immunosorbent assay.
MAIN OUTCOME MEASURES
Concentrations of PEDF and VEGF-A in aqueous.
RESULTS
At baseline, concentrations VEGF-A (3698 ± 2105 pg/mL vs. 233 ± 98 pg/mL) and PEDF (18.9 ± 11.9 ug/mL vs. 2.2 ± 0.6 ug/mL) were higher (P 0.15).
CONCLUSIONS
Aqueous concentrations of VEGF-A and PEDF were significantly elevated in eyes with neovascular glaucoma. Within one week after intravitreal injection of ranibizumab, VEGF-A concentration decreased to subnormal levels, while the PEDF concentration remained unchanged and the VEGF-A/PEDF ratio decreased.
Keywords
Discussion
Comments and discussion will appear here in a future update.